drugset
Drugs / Gendicine
last change Oct 2025 re-read 3 minutes ago

Gendicine

also known as Recombinant Human Ad-p53 Injection · Recombinant Human p53 Adenovirus Injection
Developed for
lung neoplasm · precancerous condition · pulmonary coin lesion
Investigated by
Shenzhen SiBiono GeneTech Co.,Ltd · The First Affiliated Hospital of Guangzhou Medical University

Trials 1

today NCT07150416 · Ph 2
2026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07150416 Oct 2025 → Dec 2026 expected lung neoplasm, precancerous condition, pulmonary coin lesion The First Affiliated Hospital of Guangzhou Medical University Not yet recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2016-10-10 Shenzhen SiBiono GeneTech Co.,Ltd GENDICINE ON SPOT LIGHT IN HONG KONG By Juliana Wang sibiono.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Gendicine “Gendicine® (Recombinant Human Ad-p53 Injection) is a gene therapy product approved in China.” NCT07150416 ↗
Known as Recombinant Human Ad-p53 Injection “Gendicine® (Recombinant Human Ad-p53 Injection) is a gene therapy product approved in China.” NCT07150416 ↗
Known as Recombinant Human p53 Adenovirus Injection “Recombinant Human p53 Adenovirus Injection (Gendicine®)” NCT07150416 ↗